Who is this for?
This is for people with advanced (metastatic) clear-cell kidney cancer who have not yet been treated for it — particularly those whose disease is classed as intermediate or poor risk.
Doctors sort advanced kidney cancer into “favorable,” “intermediate,” and “poor” risk using simple markers (blood counts, calcium, time since diagnosis, and how well someone feels). About three-quarters of people fall into the intermediate or poor groups — and it was in these groups that this treatment showed its clearest benefit.
What kind of trial is this?
CheckMate 214 was a large phase III randomized trial — the most rigorous kind. What makes it especially valuable is its length: the final results followed people for a median of more than nine years, the longest look yet at an immunotherapy combination used first for kidney cancer. That matters, because immunotherapy’s biggest promise is lasting benefit — and only long follow-up can prove it.
Background: teaching the immune system to fight
For years, advanced kidney cancer was treated mainly with targeted pills that choke off a tumor’s blood supply (like sunitinib). They help, but the benefit usually fades as the cancer adapts. Immunotherapy takes a completely different approach: instead of attacking the cancer directly, it frees the body’s own immune cells to do it — and when that works, the effect can be remarkably durable.
Kidney cancer is one of the cancer types most responsive to immunotherapy. CheckMate 214 combined two immunotherapy drugs — releasing two different immune brakes at once — and tested whether that beat the standard pill as a first treatment.
The trial: what was tested and how
CheckMate 214 enrolled 1,096 people with previously untreated advanced clear-cell kidney cancer. They were randomly assigned to one of two treatments:
- Nivolumab + ipilimumab: the two immunotherapy drugs together for four doses, then nivolumab alone as maintenance.
- Sunitinib: the standard targeted pill, taken daily.
The main measures — focused on the intermediate/poor-risk group — were how long people lived (overall survival), how often the cancer shrank (response), and how long it was held back.
Results: what they found
Dual immunotherapy helped people live longer — and, uniquely, produced remissions that lasted for years.
Nivolumab + ipilimumab vs sunitinib (intermediate/poor-risk)
The chance of being alive nine years later was meaningfully higher — a 31% lower risk of death (HR 0.69), a benefit that has held up across the entire follow-up.
This is the heart of it: of the people whose cancer responded, half were still in remission eight years later — the kind of durable benefit targeted pills rarely deliver.
In about 1 in 11 people, every visible trace of cancer disappeared — responses that are often deep and long-lasting.
And a striking safety point: even given for years, the two-immunotherapy combination caused fewer severe (grade 3–4) side effects than the targeted pill (49% vs 64%) — though the kind of side effects differ (see below).
How does this immunotherapy work?
The immune system has built-in “brakes” (checkpoints) that normally stop it from attacking the body — and cancers exploit these to hide. Nivolumab releases one brake (PD-1) and ipilimumab releases another (CTLA-4). Used together, they let immune cells recognize and attack the cancer. Because it retrains the immune system rather than poisoning the tumor directly, the effect can outlast the treatment itself.
What are the side effects?
Immunotherapy side effects are different from chemotherapy or targeted pills. Because the immune system is unleashed, it can sometimes attack healthy organs — causing inflammation of the skin, bowel, thyroid and other hormone glands, liver, or lungs. Most are manageable, often with steroids, but some are serious and a few can be lasting, so early recognition matters. Overall, severe side effects were actually less common than with sunitinib.
Does it help everyone with kidney cancer?
Not equally. The clear benefit was in intermediate- and poor-risk disease. In favorable-risk patients, the survival difference was not statistically clear (and sunitinib actually shrank tumors more often early on), so the choice there is more individual. This is why doctors assess risk group before deciding.
Can people stop treatment and stay in remission?
Yes, for some. A notable feature of immunotherapy is that a portion of people can stop treatment — because of side effects or after a good response — and remain in remission for years without further therapy. That “treatment-free” possibility is part of what makes the durable responses so valuable.
The bottom line
For advanced clear-cell kidney cancer, combining two immunotherapy drugs helped people live longer than the standard targeted pill — and did something targeted pills rarely do: produced deep, durable remissions, with about a third of patients alive at nine years and half of responders still in remission at eight. The benefit is clearest in intermediate- and poor-risk disease, and the immune-related side effects need attention, but nivolumab + ipilimumab has become a lasting standard first treatment for this cancer.
What this could mean for you
- Immunotherapy first. For advanced clear-cell kidney cancer, an immunotherapy-based treatment — rather than a targeted pill alone — is now standard.
- Risk group guides the choice. Dual immunotherapy showed its clearest benefit in intermediate/poor-risk disease; ask which group you’re in.
- The goal is durable remission. Unlike treatments that only hold the cancer temporarily, this can produce years-long remissions — sometimes even after stopping.
- Know the side effects. Immune-related effects can appear anywhere in the body; reporting new symptoms early makes them far easier to manage.
Questions & comments
Have a question about this research? Ask below. Questions are read and answered by the site. We can’t give personal medical advice, but we’re glad to explain the research more clearly.